deferasirox has been researched along with oxidopamine in 1 studies
| Studies (deferasirox) | Trials (deferasirox) | Recent Studies (post-2010) (deferasirox) | Studies (oxidopamine) | Trials (oxidopamine) | Recent Studies (post-2010) (oxidopamine) |
|---|---|---|---|---|---|
| 832 | 136 | 572 | 8,630 | 6 | 2,407 |
| Protein | Taxonomy | deferasirox (IC50) | oxidopamine (IC50) |
|---|---|---|---|
| Glyceraldehyde-3-phosphate dehydrogenase | Homo sapiens (human) | 8 | |
| DNA repair protein RAD52 homolog | Homo sapiens (human) | 0.779 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Applová, L; Franz, KJ; Hašková, P; Homola, P; Jansová, H; Roh, J; Šimůnek, T; Vávrová, K | 1 |
1 other study(ies) available for deferasirox and oxidopamine
| Article | Year |
|---|---|
Examination of diverse iron-chelating agents for the protection of differentiated PC12 cells against oxidative injury induced by 6-hydroxydopamine and dopamine.
Topics: Animals; Catecholamines; Deferasirox; Deferiprone; Deferoxamine; Dopamine; Iron; Iron Chelating Agents; Iron Overload; Oxidative Stress; Oxidopamine; PC12 Cells; Rats | 2022 |